Addressing Drug-Induced Liver Injury Using Adaptable Liver Model Systems

Addressing Unmet DILI Challenges: Novel Insights from Adaptable Liver Microphysiological Systems Addressing Drug-Induced Liver Injury Using Adaptable Liver Model Systems Addressing unmet workflow challenges is increasingly central to improving confidence in drug safety assessment, particularly for complex liabilities such as Drug-induced liver injury (DILI). This webinar demonstrates how liver microphysiological system (MPS) can be adapted to investigate different areas of toxicology; from lead optimization screening through to identifying and understanding species-specific risks, informing study design and the mechanistic investigation of adverse events in humans. Drawing on recent peer reviewed studies, we feature a comparative liver MPS study across human and preclinical species as a case example. We will discuss where MPS add the greatest value in identifying species specific risk, informing study design, and de risking translation to humans. The session will also explore challenges in evaluating cholestatic drug effects that cause DILI. In a side-by-side study of multiple liver MPS configurations, we highlight how biological fidelity varies across systems and what is required for mechanistic cholestasis research. Drug-induced liver injury (DILI) remains a major challenge in drug development particularly when traditional models fail to capture complex or species-specific risk. This webinar will explore how liver microphysiological systems (MPS) can be adapted to investigate different areas of toxicology – from lead optimization screening, through to identifying and understanding species-specific risks, informing study design and the mechanistic investigation of adverse DILI events in humans. Attendees will gain insight into where these approaches add the most value for reducing translational risk, increasing confidence in human safety outcomes.